Granted Patent
B2
US 9,278,100 · App. 13/341,695 · Granted Mar 8, 2016
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
Claims (6)
1. A method for treating a solid tumor in an individual comprising administering to the individual in need thereof:
(a) an anti-cancer agent; and
(b) an irreversible covalent inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
or a pharmaceutically acceptable salt thereof,
wherein the solid tumor is non-small cell lung cancer.
2. The method of claim 1 , wherein the inhibitor of Btk is administered orally.
Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0368. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME.
Recorded May 18, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038742/0371 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER.
Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038742/0064 →
MERGER
Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0359 →
MERGER AND CHANGE OF NAME
Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 7, 2012
From: HONIGBERG, LEE; VERNER, ERIK; BUGGY, JOSEPH; LOURY, DAVID; CHEN, WEI
To: PHARMACYCLICS, INC.
Reel/Frame 027666/0607 →